MDS Pharma appoints Dr Lori McDonald
This article was originally published in Scrip
MDS Pharma Services, a US contract research organisation, has appointed Dr Lori McDonald vice-president of quality and compliance. Dr McDonald will lead the company's ongoing programme to build and manage quality and regulatory compliance systems. She was previously vice-president of regulatory affairs at Alder Biopharmaceuticals. MDS Pharma Services is a business unit of MDS Inc.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.